抗菌治療の世界市場

GBI Researchが発行した調査報告書(GBIHC466MR)
◆英語タイトル:Antibacterial Therapeutics - High levels of Pipeline Innovation Focused on the Increasing Unmet Need Associated with Antibiotic Resistance
◆商品コード:GBIHC466MR
◆発行会社(リサーチ会社):GBI Research
◆発行日:2018年1月
◆ページ数:73
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD6,995 ⇒換算¥790,435見積依頼/購入/質問フォーム
Site License(同一国内共有可)USD13,990 ⇒換算¥1,580,870見積依頼/購入/質問フォーム
Enterprisewide License(複数国内共有可)USD20,985 ⇒換算¥2,371,305見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGBI Research社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GBI Research社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

Antibacterial Therapeutics – High levels of Pipeline Innovation Focused on the Increasing Unmet Need Associated with Antibiotic Resistance
Summary

Antibacterial resistance is currently believed to be responsible for over 700,000 deaths each year. As antibiotic resistance increases, due to the overuse and misuse of antibiotics, the number of avoidable deaths is expected to increase, with one study predicting there will be 10 million deaths caused by bacteria resistant to antibiotics in 2050.

There are several techniques being utilized to combat the spread of antibiotic resistance, which range from combining antibiotics to increase efficacy to reducing the use antibiotics in both humans and livestock.
However, significantly reducing the number of deaths caused by antibacterial resistance will require the development of new antibacterials that target infections caused by the most deadly and antibiotic resistant bacteria while acting on targets not currently utilized by marketed products in order to avoid cross resistance.

Without the development of innovate antibacterial products the emergence and spread of antibiotic resistance will not only increase the number of avoidable deaths caused by the infection itself, it also has the potential to increase the risks associated with surgery, while putting additional pressure on already stretched healthcare providers, as treating drug-resistant infections is considerably more expensive than treating drug-susceptible infections.

This report examines the entire antibacterial therapy area with a particular focus on four key indications, methicillin resistant staphylococcus aureus (MRSA), sepsis, pneumonia and tuberculosis, which were selected due to their pipeline size, prevalence and level of unmet need.

Scope

- The antibacterial pipeline is large, with 1,634 products in active development. Does current pipeline innovation hold the potential to affect the future antibacterial market?
- The four key indications in the antibacterial pipeline are tuberculosis, pneumonia, MRSA and sepsis. How does the composition of each pipeline compare both in terms of first-in-class and non-first-in-class innovation.
- There are 234 first-in-class products in the antibacterial pipeline. Which of these possess the greatest potential to improve disease outcome and be commercially successful, based on their target?
- Analysis of strategic consolidations and deals revealed a high level of activity between 2006 and 2017.
- A significant number of first-in-class products have been identified with no prior involvement in deals. How does deal frequency and value compare between target families and molecule types, and which first-in-class programs have not yet been involved in a licensing or co-development deal?

Reasons to buy

- Appreciate the current clinical and commercial landscapes by considering disease symptoms, pathogenesis, etiology, co-morbidities and complications, epidemiology, diagnosis, prognosis and treatment options.
- Visualize the composition of the antibacterial therapeutics market in terms of dominant molecule types and targets, highlighting what the current unmet needs are and how they can be addressed. This knowledge allows a competitive understanding of gaps in the current market.
- Analyze the antibacterial pipeline and stratify by stage of development, molecule type and molecular target.
- Assess the therapeutic potential of first-in-class targets. Using a proprietary matrix, human first-in-class targets have been assessed and ranked according to clinical potential. Promising early-stage targets have been reviewed in greater detail.
- Consider first-in-class pipeline products with no prior involvement in licensing and co-development deals, which may represent potential investment opportunities.

【レポートの目次】

1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 3
1.2 List of Figures 3
2 Executive Summary 5
2.1 Robust Pipeline Aims to Address Unmet Needs 5
2.2 High level of Innovation in the Sepsis and Tuberculosis Pipelines. 5
2.3 Opportunities to obtain innovative first-in-class products remain. 5
3 The Case for Innovation 6
3.1 Growing Opportunities for Biologic Products 7
3.2 Diversification of Molecular Targets 7
3.3 Innovative First-in-Class Product Developments Remain Attractive 7
3.4 Regulatory and Reimbursement Policy Shifts Favor First-in-Class Product Innovation 8
3.5 Sustained Innovation 8
3.6 Report Guidance 9
4 Clinical and Commercial Landscape 10
4.1 Therapy Area Overview 10
4.2 Symptoms 10
4.2.1 Pneumonia 10
4.2.2 MRSA 11
4.2.3 Sepsis 11
4.2.4 Tuberculosis 11
4.3 Diagnosis 11
4.4 Pathophysiology 15
4.5 Prognosis 17
4.5.1 Tuberculosis 17
4.5.2 Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections 17
4.5.3 Pneumonia 17
4.5.4 Sepsis 17
4.6 Treatment Options 18
4.6.1 Cell-Wall Synthesis Inhibitors 18
4.7 Overview of Marketed Products within Antibacterial Therapies 20
5 Assessment of Pipeline Product Innovation 21
5.1 Overview 21
5.2 Antibacterial Pipeline by Phase, Molecule Type and Molecular Target 21
5.2.1 Antibacterial Pipeline Overall 21
5.2.2 Key Antibacterial Indications 22
5.3 Pipeline by Molecular Target 24
5.3.1 Antibacterial Disease Overall 24
5.3.2 Key Antibacterial Indications 25
5.4 Comparative Distribution of Programs between the Antibacterial Therapeutics Market and Pipeline by Therapeutic Target Family 27
6 Signaling Pathways, and First-in-Class Molecular Target Integration. 36
6.1 The Complexity of Signaling Networks in Antibacterial therapies 36
6.2 Signaling Pathways, Disease-Causing Mutations and First-in-Class Molecular Target Integration 36
6.3 First-in-Class Target Matrix Assessment 36
6.3.1 Sepsis 37
6.3.2 MRSA 38
6.3.3 Pneumonia 38
6.3.4 Tuberculosis 39
7 First-in-Class Target and Pipeline Program Evaluation 40
7.1 Pipeline Programs that Target Monocyte Differentiation Antigen CD14 40
7.2 Pipeline Programs that Target Toll-Like Receptor 3 41
7.3 Pipeline Programs that Target Gelsolin 42
7.4 Pipeline Programs that Target NACHT LRR and PYD Domains Containing Protein 3 44
7.5 Pipeline Programs that Target Low-affinity immunoglobulin gamma Fc region receptor IIa (CD32a) 45
7.6 Pipeline Programs that Target Triggering Receptor Expressed on Myeloid Cells 1 46
7.7 Pipeline Programs that Target Furin 48
7.8 Pipeline Programs that Target Angiopoietin 2 49
8 Deals and Strategic Consolidations 51
8.1 Industry-Wide First-in-Class Deals 51
8.2 Licensing Deals 52
8.2.1 Deals by Region, Value and Year 52
8.2.2 Deals by Stage of Development and Value 53
8.2.3 Deals by Molecule Type, Molecular Target and Value 54
8.2.4 Table for Licensing Deals with a Disclosed Value 55
8.3 Co-development Deals 56
8.4 List of First-in-Class Pipeline Products with and without Prior Deal Involvement 60
9 Appendix 66
9.1 References 66
9.2 Abbreviations 69
9.3 Disease List 70
9.3.1 Tuberculosis: 70
9.3.2 Pneumonia 70
9.3.3 MRSA 70
9.3.4 Sepsis: 70
9.4 Research Methodology 70
9.4.1 Data integrity 71
9.4.2 Innovative and meaningful analytical techniques and frameworks: 71
9.4.3 Evidence based analysis and insight: 71
9.5 Secondary Research 71
9.5.1 Market Analysis 71
9.5.2 Pipeline Analysis 71
9.5.3 First-in-Class Matrix Assessment 71
9.5.4 First-in-Class Target Profiles 72
9.5.5 Licensing and Co-Development Deals 72
9.6 Contact Us 73
9.7 Disclaimer 73

1.1 List of Tables
Table 1: Antibacterial Therapeutics, Quick-Sequential Oran Failure Assessment Test Criteria 12
Table 2: Antibacterial Therapeutics, Glasgow Coma Scale 12
Table 3: Antibacterial Therapeutics, Sequential Organ Failure Assessment score 13
Table 4: Antibacterial Therapeutics, Monocyte Differentiation Antigen CD14 as a Therapeutic Target, 2017 41
Table 5: Pipeline Programs Targeting Monocyte Differentiation Antigen CD14 41
Table 6: Antibacterial Therapeutics, Toll-Like Receptor 3 as a Therapeutic Target, 2017 42
Table 7: Pipeline Programs Targeting Toll-Like Receptor 3 42
Table 8: Antibacterial Therapeutics, Gelsolin as a Therapeutic Target, 2017 43
Table 9: Pipeline Programs Targeting Gelsolin 43
Table 10: Antibacterial Therapeutics NACHT LRR and PYD Domains Containing Protein 3 as a Therapeutic Target, 2017 45
Table 11: Pipeline Programs Targeting NACHT LRR and PYD Domains Containing Protein 3 45
Table 12: Antibacterial Therapeutics, Low-affinity immunoglobulin gamma Fc region receptor IIa as a Therapeutic Target, 2017 46
Table 13: Pipeline Programs Targeting Low-affinity immunoglobulin gamma Fc region receptor IIa 46
Table 14: Antibacterial Therapeutics, Triggering Receptor Expressed on Myeloid Cells 1s as a Therapeutic Target, 2017 47
Table 15:Pipeline Programs Targeting Triggering Receptor Expressed on Myeloid Cells 1 48
Table 16: Antibacterial Therapeutics, Furin as a Therapeutic Target, 2017 48
Table 17: Pipeline Programs Targeting Furin 49
Table 18: Antibacterial Therapeutics, Angiopoietin 2as a Therapeutic Target, 2017 50
Table 19: Pipeline Programs Targeting Angiopoietin 2 50

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 抗菌治療の世界市場(Antibacterial Therapeutics - High levels of Pipeline Innovation Focused on the Increasing Unmet Need Associated with Antibiotic Resistance)]についてメールでお問い合わせはこちらでお願いします。


◆H&Iグローバルリサーチのお客様(例)◆